DCPH Deciphera Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DCPH

Price (delayed)

$14.75

Market cap

$1.12B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.37

Enterprise value

$1.08B

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase ...

Highlights
The company's EPS has surged by 54% YoY and by 32% QoQ
The net income has grown by 40% YoY and by 19% from the previous quarter
Deciphera Pharmaceuticals's quick ratio has increased by 27% YoY but it has decreased by 22% from the previous quarter
Deciphera Pharmaceuticals's equity has increased by 12% YoY but it has decreased by 9% QoQ
Deciphera Pharmaceuticals's gross margin has decreased by 3.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.deciphera.com
Peers: OVID

Key stats

What are the main financial stats of DCPH
Market
Shares outstanding
75.95M
Market cap
$1.12B
Enterprise value
$1.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.09
Earnings
Revenue
$134.04M
EBIT
-$178.21M
EBITDA
-$171.14M
Free cash flow
-$153.7M
Per share
EPS
-$2.37
Free cash flow per share
-$2.04
Book value per share
$5.06
Revenue per share
$1.78
TBVPS
$6.01
Balance sheet
Total assets
$454.04M
Total liabilities
$112.35M
Debt
$29.11M
Equity
$341.69M
Working capital
$306.49M
Liquidity
Debt to equity
0.09
Current ratio
4.54
Quick ratio
4.01
Net debt/EBITDA
0.21
Margins
EBITDA margin
-127.7%
Gross margin
93.5%
Net margin
-133.5%
Operating margin
-136.3%
Efficiency
Return on assets
-39.3%
Return on equity
-51.4%
Return on invested capital
-56.3%
Return on capital employed
-48.5%
Return on sales
-133%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DCPH stock price

How has the Deciphera Pharmaceuticals stock price performed over time
Intraday
-0.27%
1 week
-8.44%
1 month
3.44%
1 year
57.75%
YTD
-10.01%
QTD
-10.01%

Financial performance

How have Deciphera Pharmaceuticals's revenue and profit performed over time
Revenue
$134.04M
Gross profit
$125.27M
Operating income
-$182.72M
Net income
-$178.93M
Gross margin
93.5%
Net margin
-133.5%
The net margin has surged by 57% year-on-year and by 26% since the previous quarter
The company's operating margin has surged by 56% YoY and by 26% QoQ
The net income has grown by 40% YoY and by 19% from the previous quarter
The operating income has increased by 39% year-on-year and by 18% since the previous quarter

Growth

What is Deciphera Pharmaceuticals's growth rate over time

Valuation

What is Deciphera Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.92
P/S
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.09
The company's EPS has surged by 54% YoY and by 32% QoQ
The P/B is 25% below the 5-year quarterly average of 3.9 but 8% above the last 4 quarters average of 2.7
Deciphera Pharmaceuticals's equity has increased by 12% YoY but it has decreased by 9% QoQ
Deciphera Pharmaceuticals's revenue has increased by 39% YoY and by 10% QoQ
DCPH's price to sales (P/S) is 6% less than its last 4 quarters average of 8.8

Efficiency

How efficient is Deciphera Pharmaceuticals business performance
The company's return on sales has surged by 57% YoY and by 27% QoQ
Deciphera Pharmaceuticals's return on invested capital has increased by 33% YoY and by 23% QoQ
The ROA has grown by 33% YoY and by 20% from the previous quarter
The return on equity has grown by 30% year-on-year and by 21% since the previous quarter

Dividends

What is DCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCPH.

Financial health

How did Deciphera Pharmaceuticals financials performed over time
Deciphera Pharmaceuticals's current ratio has increased by 30% YoY but it has decreased by 19% QoQ
Deciphera Pharmaceuticals's quick ratio has increased by 27% YoY but it has decreased by 22% from the previous quarter
The debt is 91% smaller than the equity
DCPH's debt to equity is up by 13% from the previous quarter but it is down by 10% YoY
Deciphera Pharmaceuticals's equity has increased by 12% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.